The estimated Net Worth of Jane H Hollingsworth is at least 5.72 千$ dollars as of 31 May 2023. Jane Hollingsworth owns over 183 units of Diffusion Pharmaceuticals Inc stock worth over 5,716$ and over the last 4 years Jane sold DFFN stock worth over 0$.
Jane has made over 6 trades of the Diffusion Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Jane exercised 183 units of DFFN stock worth 805$ on 31 May 2023.
The largest trade Jane's ever made was buying 32,786 units of Diffusion Pharmaceuticals Inc stock on 13 May 2021 worth over 19,999$. On average, Jane trades about 4,213 units every 94 days since 2020. As of 31 May 2023 Jane still owns at least 1,299 units of Diffusion Pharmaceuticals Inc stock.
You can see the complete history of Jane Hollingsworth stock trades at the bottom of the page.
Jane's mailing address filed with the SEC is 300 EAST MAIN ST., SUITE 101, CHARLOTTESVILLE, VA, 22902.
Over the last 9 years, insiders at Diffusion Pharmaceuticals Inc have traded over 0$ worth of Diffusion Pharmaceuticals Inc stock and bought 61,786 units worth 39,139$ . The most active insiders traders include Robert Joseph Jr. Cobuzzi、Isaac Blech、Jane H Hollingsworth. On average, Diffusion Pharmaceuticals Inc executives and independent directors trade stock every 60 days with the average trade being worth of 26,721$. The most recent stock trade was executed by Diana M Lanchoney on 30 June 2023, trading 232 units of DFFN stock currently worth 1,021$.
diffusion pharmaceuticals is a clinical stage company focused on improving the effectiveness of standard-of-care therapies for life-threatening treatment-resistant solid cancerous tumors, without adding harmful side effects. the company is developing its lead drug, trans sodium crocetinate (tsc), which has received orphan drug designation from the fda for use in a number of cancers in which tumor hypoxia (oxygen deprivation) diminishes the efficacy of current treatments. tsc targets the cancer’s hypoxic micro-environment, re-oxygenating treatment-resistant tissue and making the cancerous cells more vulnerable to the therapeutic effects of conventional radiation and chemotherapy. the company is poised to begin a pivotal phase 3 trial in glioblastoma (gbm) in 2016. other programs include planned phase 2/3 trials in pancreatic cancer and brain metastases. because tsc’s novel mechanism safely re-oxygenates a wide range of tumor types, its use is not limited to a specific tumor tissue, but
Diffusion Pharmaceuticals Inc executives and other stock owners filed with the SEC include: